The disease is more commonly diagnosed in White women than in Black women. The overall risk of a woman developing ovarian cancer in her lifetime is one in 91, while the chance of death is an estimated one in 143.
From 1990 to the mid-2010s, the incidence rate of ovarian cancer declined between 1% to 2% per year, increasing to nearly 2% per year between 2012 and 2021. Additionally, the rate of ovarian cancer-related deaths has decreased by 43% since 1976, mainly due to advancements in treatments.2
What’s Next for LY4170156?
"We are excited to share these first clinical data for our FRα targeting ADC, demonstrating a promising tolerability and efficacy profile across all FRα expression levels," said David Hyman, MD, chief medical officer, Lilly, in the press release. "Based on these results, we believe there is the potential to significantly expand the number of ovarian cancer patients who could benefit from a FRα ADC. We are now focused on rapidly advancing this potential new medicine into registrational Phase III clinical trials."
References
1. Lilly presents first clinical data for its investigational, next-generation FRα targeting ADC in platinum-resistant ovarian cancer at the 2025 ASCO Annual Meeting. Lilly. June 2, 2025. Accessed June 11, 2025. https://investor.lilly.com/news-releases/news-release-details/lilly-presents-first-clinical-data-its-investigational-next
2. Key Statistics for Ovarian Cancer. American Cancer Society. Accessed June 11, 2025. https://www.cancer.org/cancer/types/ovarian-cancer/about/key-statistics.html